Severity
Low
FDA Drug recall · Reported February 18, 2026
Tablets/Capsules Imprinted with Wrong ID
Unichem Pharmaceuticals USA Inc. recalled Doxazosin Tablets, USP, 4 mg, 1000 tablets per bottle, Rx only, distributed by Unichem Ph… - a low-severity action.
Doxazosin Tablets, USP, 4 mg, 1000 tablets per bottle, Rx only, distributed by Unichem Ph… was recalled by Unichem Pharmaceuticals USA Inc. in February 18, 2026. Reason: Tablets/Capsules Imprinted with Wrong ID. Check the official notice for the remedy. Verify recall #D-0306-2026 with the FDA Drug before acting.
The recall
Unichem Pharmaceuticals USA Inc. issued this low-severity FDA Drug recall-Tablets/Capsules Imprinted with Wrong ID.
Sourced from official FDA Drug enforcement records. Verify recall #D-0306-2026 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0306-2026) was formally reported on February 18, 2026, with the manufacturer initiating the action on January 21, 2026. It is classified under Low severity (Class III), with a current status of Ongoing. Unichem Pharmaceuticals USA Inc. is listed as the recalling firm, operating out of East Brunswick, NJ. Federal records list the affected scope as 60,000 tablets.
The documented reason for this recall is: Tablets/Capsules Imprinted with Wrong ID Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 3,731 children & baby products recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
60,000 tablets
Related Recalls
6
0 from same agency
Doxazosin Tablets, USP, 4 mg, 1000 tablets per bottle, Rx only, distributed by Unichem Pharmaceuticals (USA), Inc., 1 Tower Center Boulevard, Suite 2200, East Brunswick, NJ 08816 USA, manufactured by Unichem Laboratories Limited, Plot Number 15 to 18, Pilerne Industrial Estate, Pilerne, Bardez, Goa (India) 403511, NDC 29300-353-10.
Tablets/Capsules Imprinted with Wrong ID
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Ongoing |
| Recall number | D-0306-2026 |
| Date reported | February 18, 2026 |
| Date initiated | January 21, 2026 |
| Recalling firm | Unichem Pharmaceuticals USA Inc. |
| Firm location | East Brunswick, NJ |
| Affected scope | 60,000 tablets |
| Distribution | Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Xishentang Dongguan Trading Co, Ltd., dba Pretty-Life, of China · 2026-07-02
Diamond Wipes International, Inc. of Chino, California · 2026-07-02
· 2026-07-02
· 2026-07-02
Sanven Technology Ltd., dba Vevor, of Rancho Cucamonga, California · 2026-07-02
Compare this recall with AMASKY Nursing Pillows Recalled Due to Risk of Serious Inju… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported February 18, 2026. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.